Mutations of HER family members result in constitutive downstream pathway signaling and are found across a spectrum of cancers; the most common mutations include EGFR/HER1 activating mutations in non–small cell lung cancer (NSCLC) and HER2 amplifications/activating mutations in breast cancer (BC) (3). This evidence concerns the gene EGFR and breast carcinoma.